Efficacy and safety of the S-1, nab-paclitaxel, and gemcitabine triplet regimen in patients with resected pancreatic ductal adenocarcinoma
ObjectiveTo evaluate the safety, feasibility, and efficacy of an S-1-based triplet regimen (with nab-paclitaxel and gemcitabine) as adjuvant therapy following curative resection for pancreatic ductal adenocarcinoma (PDAC).MethodsWe retrospectively analyzed 3-year postoperative clinical data from 92...
Gardado en:
| Principais autores: | , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Frontiers Media S.A.
2025-09-01
|
| Series: | Frontiers in Oncology |
| Assuntos: | |
| Acceso en liña: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1622215/full |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|